Literature DB >> 20871637

Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?

Kai-Uwe Eckardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20871637     DOI： 10.1038/nrneph.2010.115

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

Review 2.  Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.

Authors:  Nataliya Volkova; Lenore Arab
Journal:  Am J Kidney Dis       Date:  2006-01       Impact factor: 8.860

3.  Erythropoiesis-stimulating agents--time for a reevaluation.

Authors:  Ellis F Unger; Aliza M Thompson; Melanie J Blank; Robert Temple
Journal:  N Engl J Med       Date:  2010-01-06       Impact factor: 91.245

4.  Comparative mortality risk of anemia management practices in incident hemodialysis patients.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Jerry Avorn; Brian D Bradbury; Jun Liu; Wolfgang C Winkelmayer
Journal:  JAMA       Date:  2010-03-03       Impact factor: 56.272

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Authors:  A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

7.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

8.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

9.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Authors:  Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.